TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
Community
Main Feed
Today's Market Intel
Top Stocks
AI-Curated Stock Lists
IPO Calendar
Upcoming Listings
Stock Teasers
The Stock Behind the Promo
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
Stock Reports
AI Research Reports
Commentary
Opinionated Stock Takes
Custom Reports
Stock Deep Dives · Free to Try
AI Analyst
Agentic Chat · Free to Try
Watchlist
Track Your Stocks · Free
Spark Charts
AI Technical Analysis · Free to Try
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio · Pro
My Portfolio
Brokerage Connected · Pro
Custom Reports
Stock Deep Dives
AI Analyst
Agentic Chat
Watchlist
Your Stocks & Notes
Spark Charts
AI Technical Analysis
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Account
Plan, Billing & Appearance
Log inCreate Account
← Back to TickerSpark
▌Research Report·October 29, 2026

Illumina (ILMN): Clinical Sequencing Rebuild Gains Traction

Illumina is rebuilding growth around clinical sequencing, NovaSeq X consumables, and multi-omics, but valuation keeps the stock in Hold territory. Q3 results and raised guidance show momentum, yet the shares already price in much of the recovery.

Research ReportILMNHealthcareDiagnostics & ResearchHealthcare
By TickerSpark·October 29, 2026·16 min read

§ Product

  • How It Works
  • Custom Reports
  • AI Analyst
  • Intel Dashboard
  • Spark Charts
  • Trade Tracker
  • My Portfolio
  • Plans

§ Research

  • Main Feed
  • Community
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA

Illumina (ILMN): Clinical Sequencing Rebuild Gains Traction
B-
Overall
B+
Balance Sheet
B
Income
B+
Estimates
C+
Valuation
TickerSpark AI RatingHold
▌Investment Summary
Illumina (ILMN) is earning an overall grade of B- and looks like a Hold right now. The company is rebuilding its growth story with clinical sequencing, NovaSeq X consumables, and multi-omics, but valuation remains the main constraint. Our fair value is $250, which leaves limited upside after the recent recovery.

Thesis

Illumina (ILMN) is rebuilding its growth story around clinical sequencing, NovaSeq X consumables, and a broader multi-omics platform. Q3 2026 revenue reached $1.17B, operating margin was 25.0%, and diluted EPS was $1.44. Management also raised full-year 2026 revenue guidance to $4.64B-$4.66B and non-GAAP EPS guidance to $5.40-$5.45.

The core investment case is stronger than the 2021-2024 earnings record suggests. Clinical consumables grew 14% in Q3, more than 80 NovaSeq X systems were placed, and 84% of high-throughput consumables revenue had transitioned to the X platform. That installed base creates a recurring reagent and flow-cell revenue stream, much like a fleet of specialized machines that keeps ordering fuel.

The constraint is valuation. ILMN trades at 53.9 times trailing earnings, 45.5 times forward earnings, and 3.4 times PEG, while earnings growth in the latest core data set was down 9.4% year over year. The analyst consensus target is $248.90, with 4 Buy ratings, 6 Holds, and 2 Sells. For a moderate-risk investor, the appropriate stance is Hold, with our fair value estimate of $250.00.

Company Overview

Illumina provides sequencing- and array-based systems, consumables, software, services, and data solutions for genomic analysis. The company serves genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical and biotechnology companies, molecular diagnostic laboratories, and consumer genomics businesses.

Founded in 1998 and headquartered in San Diego, Illumina had approximately 8,600 employees in the company profile. Its products span the Americas, Europe, Greater China, Asia Pacific, the Middle East, and Africa. Core revenue was $4.34B in 2025, while the latest valuation data show a market capitalization of $43.6B, EBITDA of $1.16B, and net margin of 18.3%.

Business Segment Deep Dive

▌Common Questions

Frequently asked questions

+Is ILMN stock a buy right now?
No — Illumina is a Hold, not a Buy, because the growth rebound is real but the valuation is still demanding. Q3 showed stronger clinical sequencing demand and raised 2026 guidance, yet the stock already trades at 45.5x forward earnings and 53.9x trailing earnings.
+What is ILMN's fair value?
Illumina's fair value is $250. We arrive at that by weighing the analyst consensus target of $248.90 against the company’s improving clinical sequencing mix, NovaSeq X adoption, and 2026 guidance raise, while also recognizing that the shares still command 45.5x forward earnings and 3.4x PEG.
+
▌The Daily Briefing · Free

A new stock idea, every evening.

One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.

Creates a free TickerSpark account — newsletter included.

or with email

Daily market recap + weekly preview. One-click unsubscribe in every email.

Sequencing dominates the business. In 2025, sequencing generated $3.99B, or 91.8% of total revenue, while microarrays generated $358M, or 8.2%. The mix has remained consistent since 2023, when sequencing represented 91.3% of revenue and microarrays represented 8.7%.

The Q3 2026 product mix shows where growth is coming from. Sequencing consumables produced $748M, up 5% organically and 6% on a reported basis. Sequencing instruments generated $103M, while sequencing service and other revenue reached $158M. Clinical sequencing revenue grew 14% in the quarter, while research and applied sequencing declined 6%.

Microarrays and other revenue reached $105M in Q2 2026, up 21% on a reported basis after including SomaLogic revenue. The same category declined 4% on a rest-of-world organic basis, so its reported growth currently reflects the acquisition as much as underlying demand. This makes sequencing, especially clinical consumables, the main operating engine.

Get AI research on any stock

Instant reports, daily intelligence, and an AI analyst in your pocket.

Get Started →

Flagship Product Analysis

NovaSeq X is Illumina's flagship high-throughput sequencing platform and the central product in the current recovery. Illumina placed more than 95 NovaSeq X systems in Q2 2026 and more than 80 in Q3. By Q3, the platform represented 84% of high-throughput consumables revenue and 78% of high-throughput gigabases shipped.

The platform matters because instrument placements create future consumables demand. Management reported that 78% of clinical volume had moved to NovaSeq X in Q2 and continued to target 80%-85% conversion by the end of 2026. The company also reported more than 30% year-over-year growth in total sequencing gigabase output on connected high- and mid-throughput instruments in Q2.

NovaSeq X is not the only relevant product. Illumina also placed more than 10 NovaSeq 6000 systems in Q2, while the MiSeq i100 contributed to instrument growth. The company launched a whole-genome minimal residual disease research workflow and the StrataMap Spatial sequencing-based spatial workflow, extending the platform into oncology and tissue biology.

Innovation & Competitive Advantage

Illumina's primary advantage is the combination of installed instruments, proprietary consumables, workflow software, and customer familiarity. The 2025 10-K lists 1,380 issued U.S. patents, 1,120 pending U.S. patent applications, 7,653 issued patents outside the U.S., and 4,218 pending applications outside the U.S.

The innovation strategy is expanding beyond sequencing into multi-omics. The SomaLogic acquisition added proteomics through the SomaScan and SomaSeq offerings. BioInsight combines sequencing, perturbation tools, computing, and artificial intelligence for pharmaceutical discovery. Illumina had delivered more than 300 million cells through its Billion Cell Atlas program and had six pharmaceutical partners after adding three partners following the Q2 quarter.

The moat is real, but it is not untouchable. Customers value throughput, cost per sample, accuracy, and workflow integration, while competitors continue to invest in short-read, long-read, proteomics, and AI capabilities. BioInsight and spatial biology broaden the product set, but revenue from the Billion Cell Atlas remains early relative to the $4.34B 2025 business.

Operations & Supply Chain

The Q2 2026 operating record shows both demand strength and supply pressure. Illumina increased supply capacity enough to place more than 95 NovaSeq X systems, but it also absorbed higher freight and memory costs. Cash flow from operations was $201M in the quarter, below the usual trend because of tax-payment timing and higher inventory used to secure critical components.

Capital allocation remains active. Illumina repurchased 0.9 million shares for approximately $122M at an average price of $129.07 and reported approximately $1.8B remaining under its current repurchase authorization. Annual 2025 capital expenditures were $148M against operating cash flow of $1.08B, producing $931M of free cash flow in the financial statements.

Market Analysis

Illumina operates in a large life-science tools market supported by genomic testing, pharmaceutical research, clinical diagnostics, and laboratory automation. Market research estimates place the global life-science tools market between approximately $176.9B in 2024 and $201.4B in 2025, depending on the definition used.

Illumina has framed its own opportunity at more than $100B, with a prior 2027 total addressable market estimate of approximately $120B. The company has also described clinical sequencing as a roughly $78B portion of the 2027 opportunity and research and applied markets as approximately $23B. Those figures support a long runway, but the near-term conversion rate matters more than the headline market size.

The most important market shift is the movement from research-only sequencing toward clinical applications. Oncology, minimal residual disease, comprehensive genomic profiling, rare disease testing, and reproductive health are expanding the use case. Q3 clinical growth of 14% and U.S. and Canada clinical growth above 20% in Q2 provide direct evidence that this transition is producing current revenue.

Like what you're reading?

Get full access to AI-powered research reports, market analysis, and portfolio tools.

Get Started →

Customer Profile

Illumina's customer base spans hospitals, diagnostic laboratories, pharmaceutical companies, biotechnology companies, academic institutions, government laboratories, genomic research centers, and consumer genomics companies. Clinical customers now represent approximately 65% of sequencing consumables revenue, giving the business a larger exposure to healthcare workflows than its traditional research identity implies.

Customer behavior differs by end market. Clinical customers are expanding capacity, including multi-unit orders for new clinical trials, while research customers remain cautious because of funding uncertainty. Q3 research and applied sequencing revenue declined 6%, while clinical growth reached 14%. That divergence explains why NovaSeq X placements are strong even as the broader research market remains uneven.

Competitive Landscape

Thermo Fisher Scientific competes through Ion Torrent sequencing and a much broader life-science tools portfolio. Oxford Nanopore Technologies and Pacific Biosciences compete in sequencing, particularly in long-read and specialized applications. MGI, BGI, Complete Genomics, and Ultima Genomics add pressure in lower-cost and international sequencing markets.

Illumina's strongest position is in high-throughput short-read sequencing, where the installed base, consumables ecosystem, accuracy, and workflow integration matter. The company also competes in adjacent categories against 10x Genomics, Qiagen, Roche, and Bionano. Some of these companies compete for the same workflow budget even when they do not sell an identical sequencer.

The competitive risk is greatest when customers prioritize a specific technical feature over ecosystem continuity. Long-read systems address structural variation and complex genomic regions, while lower-cost short-read systems pressure price per sample. Illumina's response is to lower end-to-end cost, expand workflow breadth, and use NovaSeq X volume to deepen consumables pull-through.

Macro & Geopolitical Landscape

China is the clearest geopolitical risk. Chinese authorities added Illumina to the List of Unreliable Entities on February 4, 2025, and export restrictions on sequencing instruments followed on March 4, 2025. China later permitted exports to resume on November 10, 2025, subject to case-by-case approval. The company continues to separate certain growth measures from Greater China.

Tariffs and trade barriers add a second layer of risk. Illumina's February 12, 2026 10-K identifies tariffs, import and export licensing, customs duties, sanctions, and trade restrictions as factors that can affect costs and revenue. Q3 2026 results also included tariff-related adjustments, making reported figures less clean than the underlying operating metrics.

Research funding is another macro variable. The 10-K identifies reductions in National Institutes of Health funding and targeted cancellations of U.S. government grants or contracts as risks to customer demand. That pressure is visible in the research and applied consumables decline, while clinical demand provides a partial counterweight.

Balance Sheet Health

▌Premium Members Only

Cash and marketable securities totaled $1.71B against $1.24B of debt, while the current ratio stood at 3.0x and the quick ratio at 2.4x.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Income Statement Strength

▌Premium Members Only

Q3 2026 revenue reached $1.17B with a 25.0% operating margin and diluted EPS of $1.44, while core earnings growth was still down 9.4% year over year.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Estimates Outlook

▌Premium Members Only

Management lifted 2026 revenue guidance to $4.64B-$4.66B and non-GAAP EPS guidance to $5.40-$5.45 after a stronger-than-expected quarter.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Valuation Assessment

▌Premium Members Only

The stock trades at 53.9x trailing earnings, 45.5x forward earnings, and 3.4x PEG, leaving little room for disappointment despite improving fundamentals.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Target Prices & Recommendation

▌Premium Members Only

Analyst consensus sits at $248.90 with 4 Buy ratings, 6 Holds, and 2 Sells, closely matching the report's $250 fair value view.

Unlock the full analysis

Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.

Get Full Access →

Closing

Illumina has moved from restructuring and multiyear losses toward a credible operating recovery. The evidence is tangible: 2025 net income of $850M, Q3 2026 EPS of $1.44, a 25.0% operating margin, 14% clinical growth, and more than 80 NovaSeq X placements in the quarter.

The next phase depends on converting those placements into recurring consumables revenue while controlling supply costs and expanding clinical workflows. At our fair value estimate of $250.00, ILMN is a Hold rather than a bargain. A material pullback toward the Buy level would improve the setup; a rally toward the Sell level would make the recovery story increasingly expensive.

What is driving Illumina's growth?
Clinical sequencing is the key driver, with that business growing 14% in Q3 and representing about 65% of sequencing consumables revenue. NovaSeq X is also gaining traction, with more than 80 systems placed in Q3 and 84% of high-throughput consumables revenue already on the platform.
+Why isn't ILMN rated a Buy if growth is improving?
The main reason is valuation: the stock trades at 53.9 times trailing earnings and 45.5 times forward earnings even after the rebound. Growth is improving, but earnings were still down 9.4% year over year in the latest core data set, so the risk/reward is not compelling enough for a Buy.
+How strong is Illumina's balance sheet?
Illumina's balance sheet looks solid, with $1.71B in cash and marketable securities versus $1.24B of debt. Liquidity is also healthy, with a current ratio of 3.0x and a quick ratio of 2.4x.
▌For Active Investors

Want Reports Like This on Any Stock?

Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.

Get Full Access →

Not ready to subscribe? ·

▌For Active Investors

Stock research for every investor

  • Reports on any stock
  • Daily market intelligence
  • AI analyst in your pocket
  • Portfolio analysis tools
Get Full Access →

Cancel anytime

▌The Daily Briefing · Free

A new stock idea, every evening.

One stock worth watching each weekday, free in your inbox.

Creates a free TickerSpark account — newsletter included.

or with email

Daily market recap + weekly preview. One-click unsubscribe in every email.

▌More on ILMN

More to read

All articles
Illumina, Inc. (ILMN) falls 13% After Q3 Earnings
ILMN

Illumina, Inc. (ILMN) falls 13% After Q3 Earnings

Illumina, Inc. (ILMN) falls after-hours after its Q3 report, even as the company raised full-year guidance. Investors are focusing on a slight revenue miss, China-related pressure, and a premium valuation that leaves little room for disappointment.

Oct 30·5 min
Illumina, Inc. (ILMN) falls 11.7% after Q3 revenue miss
ILMN

Illumina, Inc. (ILMN) falls 11.7% after Q3 revenue miss

Illumina, Inc. (ILMN) falls sharply after reporting third-quarter results that beat adjusted profit estimates but missed on revenue. The company also raised full-year guidance, yet investors focused on the sales shortfall and the stock’s extended-hours drop.

Oct 29·5 min
Illumina, Inc. (ILMN) rises on S&P 500 inclusion
ILMN

Illumina, Inc. (ILMN) rises on S&P 500 inclusion

Illumina, Inc. (ILMN) rises after S&P Dow Jones Indices confirmed the company will join the S&P 500 on Sep. 21. The stock also drew support from solid Q2 results, raised full-year guidance, and heavier trading volume, though shares now sit above consensus analyst targets.

Sep 15·5 min